Company research
MANGOCEUTICALS, INC.
CIK 1938046Updated Sep 24, 2026
SecurityMGRX · NASDAQ · equity
Name history
MANGOCEUTICALS, INC. · through Aug 21, 2026
MGRX price & chart
Loading TradingView…
NASDAQ:MGRX on TradingView ↗In the news
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds ↗
Recent filings
Termination of a Material Definitive Agreement
Items 1.02, 9.01
10-Q filing
425 filing
425 filing
425 filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
425 filing
425 filing
Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 1.01, 5.02, 5.03, 7.01, 9.01
S-8 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 16,089,573Source | 15,370,511Source | 1,050,793Source | 1,003,287Source |
| Property, Plant and Equipment, NetUSD | 1,794Source | 2,806Source | 96,129Source | 117,499Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 14,232,484Source | 15,232,617Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,486,338Source | 58,653Source | 739,006Source | 682,860Source |
| Inventory, NetUSD | — | — | 18,501Source | — |
| Assets, CurrentUSD | 1,547,434Source | 75,595Source | 818,460Source | 694,605Source |
| Operating Lease, Right-of-Use AssetUSD | 307,861Source | 59,493Source | 119,262Source | 174,241Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 890,568Source | 1,425,463Source | 276,039Source | 389,257Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,589Source | 325Source | 2,142Source | 1,337Source |
| Additional Paid in CapitalUSD | 55,524,812Source | 35,587,858Source | 12,000,785Source | 2,628,449Source |
| Retained Earnings (Accumulated Deficit)USD | -40,647,480Source | -20,806,595Source | -11,228,173Source | -2,015,756Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,760Source | -9,845Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 15,200,547Source | 13,946,129Source | 774,754Source | 614,030Source |
| Liabilities and EquityUSD | 16,089,573Source | 15,370,511Source | 1,050,793Source | 1,003,287Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 890,568Source | 1,425,463Source | 211,078Source | 260,577Source |
| Operating Lease, Liability, CurrentUSD | 307,823Source | 64,962Source | 63,718Source | 56,725Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 64,961Source | 128,680Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -1,542Source | -1,081Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -20,643,455Source | -8,707,226Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | 9,936Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,168,280Source | 248,682Source | 624,463Source | 234,088Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | — | — | 18,501Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,850,255Source | -4,863,776Source | -6,997,375Source | -1,346,518Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 65,000Source | -3,519Source | -43,102Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 3,519Source | 43,102Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 7,270,855Source | 4,128,268Source | 7,057,040Source | 2,049,930Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | 56,146Source | 660,310Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,486,338Source | 58,653Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 248,682Source | 624,463Source | 82,267Source |
| Amortization of Intangible AssetsUSD | 1,122,639Source | 721,533Source | — | — |
| DepreciationUSD | 1,012Source | 9,936Source | 24,889Source | 3,863Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | -18,387Source | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | 18,387Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | -125,624Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -19,388Source | — | — | — |
| General and Administrative ExpenseUSD | 3,756,373Source | 3,000,571Source | 3,319,417Source | 1,643,572Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 1,239,942Source | — | — | — |
| InterestExpenseNonoperatingUSD | 103,513Source | 13,700Source | — | — |
| Inventory Write-downUSD | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -20,642,994Source | -8,706,145Source | -9,212,417Source | -1,998,055Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -461Source | -1,081Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -21,818,994Source | — | — | — |
| Nonoperating Income (Expense)USD | -2,611,106Source | -735,233Source | 6,473Source | -6,473Source |
| Operating ExpensesUSD | 18,282,735Source | 8,351,957Source | 9,650,391Source | 1,996,432Source |
| Proceeds from Issuance of Common StockUSD | 4,625,355Source | 1,328,268Source | 6,200,000Source | 2,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 456,021Source | 615,873Source | 731,493Source | 8,939Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -18,032,349Source | -7,971,993Source | -9,218,890Source | -1,991,582Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -20,643,455Source | -8,707,226Source | -9,212,417Source | -1,998,055Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -461Source | -1,081Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -20,642,994Source | -8,706,145Source | -9,212,417Source | -1,998,055Source |
| Earnings Per Share, BasicUSD per share | -2.17Source | -4.84Source | -0.57Source | -0.19Source |
| Earnings Per Share, DilutedUSD per share | -2.17Source | -4.84Source | -0.57Source | -0.19Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 10,071,609Source | 1,978,966Source | 16,113,029Source | 10,798,083Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 10,071,609Source | 1,978,966Source | 16,113,029Source | 10,798,083Source |
| Interest Expense (non-operating)USD | 103,513Source | 13,700Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,122,639Source | 721,533Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | -125,624Source | — | — | — |
| General and Administrative ExpenseUSD | 3,756,373Source | 3,000,571Source | 3,319,417Source | 1,643,572Source |
| Gross ProfitUSD | 250,386Source | 379,964Source | 431,501Source | 4,850Source |
| Interest ExpenseUSD | — | — | — | 6,473Source |
| Labor and Related ExpenseUSD | 1,348,051Source | 1,063,781Source | 977,890Source | — |
| Marketing and Advertising ExpenseUSD | 822,860Source | 1,478,663Source | 2,097,505Source | 352,860Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -21,818,994Source | — | — | — |
| Nonoperating Income (Expense)USD | -2,611,106Source | -735,233Source | 6,473Source | -6,473Source |
| Operating ExpensesUSD | 18,282,735Source | 8,351,957Source | 9,650,391Source | 1,996,432Source |
Filing attachments
ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination Dallas, Texas - August 4, 2026 - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in …
Read attachment ↗ex99-1.htm · 8-K · 2026-07-30
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology Business Combination Agreement to Bring Nuclea’s Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS - July 30, 2026 - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that it has entered into a definitiv…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-17
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and Pea…
Read attachment ↗